Short Interest in DBV Technologies S.A. (NASDAQ:DBVT) Increases By 297.0%

DBV Technologies S.A. (NASDAQ:DBVT) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,330,000 shares, a growth of 297.0% from the October 15th total of 335,000 shares. Currently, 1.4% of the company’s stock are short sold. Based on an average daily volume of 655,300 shares, the short-interest ratio is presently 2.0 days.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright increased their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. Finally, StockNews.com began coverage on DBV Technologies in a report on Wednesday, November 6th. They issued a “hold” rating for the company.

DBV Technologies Trading Down 2.2 %

Shares of NASDAQ DBVT traded down $0.01 during trading hours on Wednesday, hitting $0.62. The company had a trading volume of 72,309 shares, compared to its average volume of 231,567. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.14. The firm’s 50 day moving average is $0.74 and its 200-day moving average is $0.90.

DBV Technologies shares are set to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.